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Prion diseases are characterised by the conversion of a cellular prion protein (PrPC) by its misfolded, hence pathogenic, isoform (PrPSc). The
efficiency of this transition depends on the molecular similarities between both interaction partners and on the intrinsic convertibility of PrPC.
Transgenic mice expressing chimeric murine/ovine PrPC (Tgmushp mice) are susceptible to BSE and/or scrapie prions of bovine or ovine origin
while transgenic mice expressing similar murine/bovine PrPC chimera (Tgmubo mice) are essentially resistant. We have studied this phenomenon
by cell-free conversion on procaryotically expressed chimeric PrPC. Mouse passaged scrapie or BSE PrPSc was used as a seed and the conversion
reaction was carried out under semi-native conditions. The results obtained in this assay were similar to those of our in vivo experiments. Since
mubo- and mushp-PrPC differ only at four amino acid positions (S96G, N142S, Y154H and Q185E), single or double point mutations of mushp-
PrPC were examined in the cell-free conversion assay. While the scrapie Me7 prion induced conversion was largely reduced by the N142S and
Q185E but not by the S96G and Y154H mutation, the BSE induced conversion was retained in all mutants. Newly formed PrPres exhibited strain
specific characteristics, such as the localisation of the proteinase K cleavage site, even in the chimeric PrPC mutants. We therefore postulate that
the efficiency of the conversion of chimeric PrPC depends on the amino acid sequence as well as on prion strain specific effects.
© 2006 Elsevier B.V. All rights reserved.Keywords: Prion; BSE; Scrapie; Conversion; Species barrier1. Introduction
Transmissible spongiform encephalopathies (TSEs) or prion
diseases are fatal neurological disorders which include among
others, scrapie in small ruminants, BSE in cattle and
Creutzfeldt–Jacob disease in humans. Prion diseases are
supposedly caused by the conversion of the cellular prion
protein (PrPC) into an abnormal conformational isoform (PrPSc)
[1,2]. However, the molecular mechanism of this conversion
process is still not fully understood. The formation of PrPSc is
associated with an increase in the β-sheet content of the prion
protein. This results in a partial resistance to proteases such as
proteinase K (PK) and the tendency to form amyloid fibrils. Due
to this insolubility, a high-resolution structure of PrPSc cannot⁎ Corresponding author. Tel.: +49 38351 7163; fax: +49 38351 7191.
E-mail address: martin.groschup@fli.bund.de (M.H. Groschup).
0925-4439/$ - see front matter © 2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2006.10.009be analysed to date, whereas the structure of the α-helical and
hence more soluble PrPC has been revealed by nuclear magnetic
resonance analysis [3].
Various studies of familial human TSEs have indicated a
coherence between the amino acid sequence of the host PrPC
and both the incubation time and the disposition to develop a
spongiform encephalopathy [4]. There are about 20 point
mutations or other polymorphisms known to be associated with
the occurrence of human TSEs [5]. It has also been
demonstrated that the substitutions of few or even single
amino acids have the ability to alter either the incubation time or
actually the probability to develop clinical disease [6].
In sheep nine different alleles/polymorphisms out of the 256
amino acids of the prion protein have been described. Out of
these, the polymorphisms at amino acids 136, 154 and 171 have
been linked with the susceptibility to classical scrapie and BSE
infections and are currently used in the European Union for
breeding programs to generate resistant sheep [7,8]. Another
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to atypical scrapie [9]. Other than in sheep only one amino acid
polymorphism (introduction of an additional six octapeptide
sequence) has been revealed in cattle which, however, is not
modulating the BSE prion susceptibility [10].
The molecular mechanism by which these mutations in PrP
control the incubation times is not as yet understood. The
species barrier phenomenon, i.e. the reduced efficiency of prion
transmission to a new host species, is primarily believed to
result from the inefficient interaction between PrPSc and PrPC
from the two different species. Moreover, independent from this
effect a variety of different prion strains has been found. Some
strains propagate only inefficiently in some animal species,
while others replicate very well. Prion strains can also be
distinguished by distinct incubation times in different host
species, by distinct neuropathological lesion profiles in defined
mouse lines and, as revealed by western blot analysis, by
differences in the PK resistance and in the glycosylation
patterns of the abnormal PrPSc [11,12].
In order to overcome the species barrier for the transmis-
sion of human or ruminant derived prions to mice, a number
of transgenic mouse models have been developed in which the
human, bovine or ovine PrPC is overexpressed [14,15,17,18].
For example, Tgbov XV mice exhibit significantly shorter
incubation times following inoculation with cattle derived
BSE prions (220–240 days) than conventional RIII mice (well
over 330 days) [14]. Moreover, these incubation times are not
further shortened during the secondary passage. Furthermore,
by parallel end point titrations it was shown that these mice
are approximately 10,000 times more susceptible to a BSE
infection than RIII mice and are about ten times more
susceptible than cattle [16]. However, in humanized and
bovinized transgenic mice this PrPC replacement strategy only
worked well when the endogenous mouse PrPC expression
was ablated [17]. On the other hand, human prions could also
be efficiently transmitted into transgenic mice expressing aFig. 1. Amino acid sequence alignment of mouse, hamster, human bovine and sheep
chimera. Residues demarked ‘X’ specify the proposed protein X binding sites, while r
which are responsible for intra- and inter-species binding and barrier effects in bovine
sequences (mushp, yellow) or bovine sequences (mubo, green) were introduced betw
whose effects on the convertibility were examined.chimeric PrPC in which the core part of murine PrPC (amino
acids 94–188 of hamster PrP) was substituted by human
sequences when they coexpressed wild-type murine PrPC [18].
This phenomenon gave rise to the protein X hypothesis which
postulates that murine cofactors obligatorily needed for the
human PrPC conversion would bind with high affinity to
murine PrPC, if coexpressed and thereby block the conversion
of the transgene-encoded PrPC. As human/murine chimeric
PrPC expressing transgenic mice were equally susceptible to a
CJD infection, it was concluded that the authentic binding
sites for protein X would also be provided by the chimeric
protein.
Chimeric mushp-PrPC overexpressing transgenic mice were
almost equally susceptible to ovine and bovine TSE isolates as
wild-type ovine PrPC overexpressing transgenic mice (results
described in this paper). However, a different effect was ob-
served in bovine/murine chimeric PrPC overexpressing trans-
genic mice which were almost completely resistant to a BSE
infection, even in the absence of an endogenous murine PrPC
expression [13,16]. Interestingly, mubo-PrPC and mushp-PrPC
differ in just four amino acids at residues 96, 142, 154 and 185
(Fig. 1). Therefore we used these models to examine the in-
fluence of the primary structure of PrPC on the protein inter-
action and the convertibility during the initial steps of the
prion cascade. For this analysis we used a cell-free conversion
assay in which the conversion reaction can be mimicked by
incubating highly purified PrPC molecules together with PrPSc
seeds in an appropriate conversion buffer [19]. Under these
conditions it was shown that PrPSc itself is able to induce the
conversion of PrPC into a partially proteinase K resistant form
which is designated PrPres. This newly formed PrPres can be
selectively detected and quantified by an antibody that reacts
to an epitope tag which is absent in the original PrPSc seed
[20,21]. As the results obtained using the cell-free assay were
generally in line with in vivo data, this method offers the
possibility to simulate – in a first approach – PrPC conversionprion protein (residues 90–232) as well as of bovine/mouse and ovine/mouse
esidues 183 and 185 are supposed to determine the primary PrP interac tion sites
PrP. Chimeric PrPCs are composed of murine sequences (blue) into which sheep
een amino acids 94 and 188. Mubo and mushp differ in four amino acids (red),
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time, work and life consuming transgenic mouse challenge
experiments.
2. Materials and methods
2.1. Generation of chimeric transgenic mice
The generation and characterisation of murine/bovine PrP transgenic mice
(Tgmubo XIII) has been described earlier [14].
Murine/ovine PrP transgenic mice (Tgmushp XIX) were prepared accord-
ingly. Briefly, the open reading frame sequence coding for the core region of the
ovine PrP from aa 94 to 188 of murine PrP (98 to 192 of ovine PrP) with the
amino acids alanine (A), arginine (R), and glutamine (Q) at positions 136, 154
and 171 (PrPARQ allele) was PCR amplified. This PCR step introduced a KpnI
digestion site and at the same time a point mutation from serine (ovine sequence)
to threonine (murine sequence) at codon 98 of the ovine PrP sequence (codon 94
of the murine PrP) by PCR-mutagenesis using the primers ovPrPHG2.seq 5′
GGG GTC AAG GTG GTA CCC ACA GTC 3′ and ovPrPHG3.rev 5′ GGT
GGT GGT GAC CGT GTG TTG C 3′ leaving the BstEII digestion site at codon
189 (codon 193 of ovine PrP) intact. The fragment was then cloned into the
vector muboPrPHG coding for the murine/bovine chimeric PrP [14] that had
been digested with KpnI and BstEII. The resulting transgene construct
mushpPrPHG was microinjected into oocytes of PrP0/0 mice.
Five transgenic mouse lines were identified that expressed the murine/ovine
chimeric PrP in their brains at a level that was at least as high as in the ovine
brain, out of which the mouse line Tgmushp XIX displayed with 8–16 fold the
highest overexpression. Therefore this mouse line was selected for comparative
mouse bioassays.
2.2. Transgenic mouse challenge studies
Challenge studies were performed to compare the susceptibility of
Tgmubo and Tgmushp mice with that of the respective mouse lines expressing
full-length ovine and bovine PrP. One line of each transgene construct with the
highest brain expression level was selected for comparative transmission
studies. These were the lines Tgbov XV (16 fold overexpression), Tgmubo
XIII (16 fold overexpression), Tgshp XI (4–8 fold overexpression) and
Tgmushp XIX (8–16 fold overexpression). All challenged mice were on a
PrP-ablated background. Ten or 15 mice (depending on the availability of
inoculum and on the expected survival times of the mice) were inoculated
intracerebrally (i.c.) with 20 μl plus 100 μl intraperitoneally (i.p.) of a 10%
brain homogenate of the following BSE and scrapie isolates: BSE BBP12/92
which had already been used for a parallel BSE titration experiment in Tgbov
XV mice, a German field scrapie isolate designated ‘Potsdam’ derived from an
animal carrying the PrPARQ/ARQ allele, and the mouse passaged scrapie strains
Me7 (passaged in C57Bl mice), 22A (passaged in C57Bl mice), and Chandler
(passaged in CD1 mice).
Mice were supervised at least twice weekly for the onset of clinical
symptoms. Animals showing signs of disease were sacrificed and the mouse
brains were tested for the accumulation of PrPSc by western blot or
immunohistochemical methods.
2.3. Detection of PrPSc accumulation in the brains of challenged
transgenic mice
2.3.1. Preparation of scrapie-associated fibrils (SAF) and immunoblot
Two hundred microliters of a 10% mouse brain homogenate were incubated
with 50 μg/ml proteinase K (PK; Roche, Mannheim, Germany) for 60 min at
37 °C to completely digest all PrPC. The reaction was stopped by the addition of
10 mM PMSF (phenylmethylsulfonylfluoride) and incubated at 95 °C for 5 min.
After adding sarcosine to a final concentration of 10% and Tris–HCl (pH 7.4) to
10 mM, the samples were incubated at room temperature for 15 min. The
samples were then carefully loaded over 250 μl of a 10 mM Tris–HCl solution
(pH 7.4) containing 10% sucrose and centrifuged at 540 000 g for 45 min. The
pellets were resuspended in 40 μl gel loading buffer containing 2% SDS and
incubated at 95 °C for 5 min.2.3.2. Immunohistochemical examination
Mouse brain sections were pre-treated (incubation of the slides in formic
acid for 15 min, incubation with 4 μg/ml Proteinase K at 37 °C for 15 in and
hydrated autoclaving for 15 min) in order to improve the accessibility of the
antibody epitopes. Slides were then incubated with mab L42 [22] at an
appropriate concentration. A biotinylated goat-anti-mouse conjugate (Vector,
Burnigame, CA, USA) visualized the binding of the primary antibody. For
signal detection, an avidin–biotin-complex system (Vectastain ABC Elite Kit) in
combination with the VIP substrate (Vector, Burlingame) was applied.
2.4. Mutation of Prnp
Amino acids at residues 96, 142, 154 and 185 of mushp-PrPC were
substituted by those of mubo-PrPC. The mutations were carried out by a two step
PCR using first internal primers for the particular substitution and external
primers for the amplification of the mutant template in a second step. The mutant
mushp-PrPC was appropriately named depending on the particular substitution.
Using the primers which are listed below and Prnpmushp as a template, point
mutations were introduced to alter residues 96 (mushp-PrPC S96G), 142 (mushp-
PrPC N142S), 154 (mushp-PrPC Y154H) and 185 (mushp-PrPC Q185E).
Mutation at residue 96 was carried out by the use of 5′-GGT ACC CAC
GGT CAG TGG AAC-3′ as N-terminal internal primer and 5′-GTT CCA CTG
ACC GTG GGTACC-3′ as C-terminal internal primer. Mutation at residue 142
was carried out using 5′-CAT TTT GGC AGT GAC TAT GAG-3′ as N-terminal
internal and 5′-CTC ATA GTC ACT GCC AAA ATG-3′ as C-terminal internal
primer. Mutation at residue 154 was carried out using 5′-GAA AAC ATG CAC
CGT TAC CCC-3′ as N-terminal internal primer and 5′-GGG GTA ACG GTG
CAT GTT TTC-3′ as C-terminal internal primer. Finally mutation at residue 185
was carried out using 5′-ACA GTC AAG GAA CAC ACA GTC-3′ as N-
terminal internal primer and 5′-GAC TGT GTG TTC CTT GAC TGT-3′ as C-
terminal internal primer.
5′-CG GGA TCC AAA AAG CGG CCA-3′ and 5′-GG AAG CTT GGA
TCT TCT CCC GTC G-3′ were used as external primers.
Successive mutations were accomplished by the use of PrnPmushp S96G as a
template and the primers for substitution of residue 142 (mushp-PrPCS96G/
N142S) and mushp-PrnPCS96G/N142S as a template and the primers for
mutation at residue 154 respectively mushp-PrPC S96G/N142S/Y154H).
2.5. Expression and purification of recombinant PrPC
The gene coding for either mubo-PrPC or mushp-PrPC was amplified from
the ORF 23–231 by PCR using the primers 5′-CG GGATCC AAA AAG CGG
CCA-3′ and 5′-GG AAG CTT GGATCT TCT CCC GTC G-3′. Using the Bam
HI and HindIII cleavage sites, the amplified gene was cloned into the E. coli
vector pQE 40 (Qiagen) which harbours a N-terminal histidine (his)-tag.
Expression was carried out in Mi 5-cells (Qiagen) which were cultivated at
37 °C in 500 ml LB medium to an optical density of 0.6 at 600 nm. After the
addition of Isopropyl-β-d-thiogalactopyranoside (to a final concentration of
1 mM) the cultures were grown for another 4.5 h and the bacteria harvested by
centrifugation at 3600g and 4 °C for 10 min. Purification was carried out
according to the manufacturer's instruction under denaturing conditions (8 M
Urea). Refolding was accomplished by dialysis in 20 mM HEPES (Roth)
containing 0.2% 5 M EDTA and 0.1% N-lauroylsarcosine sodium salt (Sigma
Aldrich).
2.6. Preparation of PrPSc
PrPSc was purified from terminally scrapie diseased mouse brains (C57Bl/6)
(mouse scrapie Me7 as well as mouse passaged BSE). The preparation was
performed according to the method described by Caughey et al. [19] with some
modifications. Briefly, 1 g mouse brain samples were homogenised on ice in
15 ml TEND buffer (10 mM Tris, pH 8, 3, 1 mM EDTA, 130 mM NaCl)
supplemented with 10% N-lauroylsarcosine sodium salt as well as protease
inhibitors (1 mM DTT, 0.1 mM Pefabloc, 0.5 μg/ml Leupeptin, 1 μg/ml
Aprotinin, 0.7 μg/ml Pepstatin) and centrifuged for 30 min at 23 000 rpm (4 °C)
in a TLA 100.4 rotor (Beckman). The supernatant was collected and centrifuged
for 2.5 h at 58 000 rpm (4 °C). The resulting pellet was resuspended in 15 ml
TEND buffer containing 10% NaCl and 1% Sulfobetain SB-14 and centrifuged
Fig. 2. (A) Immunoblot of a cell-free conversion reaction using ARQ. The newly
formed PrPres fragment is detected by mab L42, if recombinant PrPC (lane 1)
changed its conformation into a partially PK resistant form, which is
characterised by a molecular mass of about 17 kDa after PK treatment (lanes
4–6). As mab L42 does not detect mouse PrPSc, the blotting membranes were
washed with glycine buffer pH 2.0 to wash off mab L42 prior to an incubation
with the polyclonal antibody Ra10 (B) which detects the murine Me7-PrPSc seed
(lanes 3–6).
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was resuspended in 8.8 ml TMS buffer which was supplemented with 10%NaCl
and 0.5% SB-14. After homogenisation the suspension was carefully loaded
onto a sucrose cushion (1.0 M sucrose, 0.1 M NaCl, 0.5% SB-14) and
centrifuged at 68 000 rpm for 1.5 h at 20 °C. The remaining pellet was
resuspended in 200 μl PBS containing 0.5% SB-14, homogenised, sonified and
finally stored at −20 °C.
2.7. PrP cell-free conversion assay
The conversion reaction was carried out using equimolar amounts of PrPC
and PrPSc as determined by immunoblotting using a recombinant PrPC
standard. Generally, the amounts of protein used were between 500 and
800 μg. After an incubation for 3 days at 37 °C in a defined semi-native
buffer (50 mM citrate pH 6.0, 200 mM KCl, 5 mM MgCl2, 1.25% N-
lauroylsarcosine) the samples were treated with proteinase K (PK) diluted in
TN buffer (0.15 M NaCl, 0.05 M Tris–HCl pH 7.4) to a concentration of
30 μg/ml. After 1 h at 37 °C the reaction was stopped with 10 mM phenyl
methansulfonyl fluoride (PMSF). A carrier protein (20 μg thyreoglobuline)
was added to the samples prior to an incubation with 200 μl methanol at
−20 °C for at least 1 h. Precipitated proteins were pelleted by centrifugation
at 13 000 rpm for 15 min (20 °C) in a table top centrifuge. Each experiment
included control samples which did not contain any PrPSc (Fig. 2, lanes 1, 2),
which were not digested with PK (lane 1) or which were not incubated for 3
days at 37 °C but instead immediately stored at −20 °C (lane 3).Table 1
Average incubation times in days of transgenic mice that had accumulated PrPSc in the
i.p. inoculation of BSE and scrapie
Mouse line Inoculum Sheep scrapie ‘Potsdam’ BSE BBP12/92
Tgbov XV 195 8/8 SEM=5.74 230 7/7 SEM=7.48
Tgmubo XIII 555 4/9 SEM=47.48 599 6/10 SEM=77.64
Tgshp XI 202 4/4 SEM=11.96 305 5/5 SEM=29.58
Tgmushp XIX 259 7/9 SEM=12.42 382 9/9 SEM=18.73
SEM=standard error of the mean.
All animals were euthanized after the onset of clinical symptoms or after 800 days2.8. SDS-PAGE and immunoblotting
Following centrifugation the pellets were resuspended in a loading buffer
(1% SDS, 25 mM Tris/HCl pH 7.4, 0.5% mercaptoethanol, 0.001%
bromphenolblue) and incubated at 95 °C for 5 min. 15 μl of each sample was
separated in a 16% acrylamide gel. Proteins were then transferred onto PVDF
membranes by semi-dry electroblotting. The membranes were incubated with
blocking buffer (PBS, 0.1% Tween, 5% skimmed milk powder) at room
temperature for 30 min, followed by an incubation for 1 h with the monoclonal
antibody mab L42 [22] that specifically binds to ruminant PrP but not to murine
PrP in order to detect the newly formed PrPres. Afterwards, the membranes were
washed three times for 10 min in PBS, 0.1% Tween. The proteins were
visualized by using an alkaline phosphatase conjugated goat anti-mouse
secondary antibody and the chemiluminescence detection substrate CDP-Star
(Tropix).
After treating the membranes with power strip buffer (0.2 M glycin, 1%
SDS, pH 2) two times for 10 min PrPSc was detected by using a polyclonal
antibody pab Ra10 [23,24] that does not detect ruminant PrP, but specifically
binds to murine PrP, and visualized by goat anti-rabbit AP and CDP-Star.
2.9. Quantification and determination of molecular mass
Chemiluminescence signals were detected using the BioRad VersaDoc™
photo imaging system and analysed by the Quantity One quantification software
(BioRad). The conversion rate was defined as the average rate of five
independent reactions. Efficiencies were calculated as the percentages of PrPC
converted into newly formed PrPres.
Determination of molecular masses was carried out using a custom-
designed protein ladder, which ranged between 16 and 23 kDa in steps of
1 kDa (FLI marker). Each of the proteins harboured an amino-terminal his-tag
and could therefore be detected by an anti-histidine antibody (RGS-His.,
Qiagen).3. Results
3.1. Generation and challenge of transgenic mice
Chimeric murine/ovine (Tgmushp XI) and murine/bovine
PrPC (Tgmubo XIII) overexpressing transgenic mice were
generated in which residues 94–188 represented ruminant
PrPC. Transgenic lines were selected in which the transgene
expression was about 8–16 fold higher than the PrPC
expression in nontransgenic mice. All transgenic mice used
in these challenge experiments were on a wild-type PrPC
ablated genetic background. These challenge experiments
showed that chimeric Tgmushp XIX mice are almost as
susceptible to cattle derived BSE, to sheep derived scrapie as
well as to mouse passaged scrapie 22A as their non-chimeric
counterpart, Tgshp XI. Meanwhile, their susceptibility to the
mouse passaged scrapie strains Me7 and Chandler wasir brains (as detected by immunoblot and/or immunohistochemistry) after i.c. and
ME7 22A Chandler
>377 0/4 >769 0/2 >470 0/6
>610 0/5 565 6/7 SEM=28.03 749 2/9 SEM=0
209 6/6 SEM=17.41 282 5/8 SEM=20.93 224 5/5 SEM=20.14
182 4/4 SEM=1.6 358 5/5 SEM=16.71 152 15/15 SEM=7.89
at the end of the experiment.
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hand, Tgmubo XIII mice displayed long incubation times of
over 550 days after being challenged with BSE and field
scrapie as well as the mouse passaged scrapie strain 22A.
These mice proved to be essentially resistant to an infection
with the mouse passaged scrapie strains ME7, where no
mouse developed disease at all, and Chandler, where two out
of seven mice developed disease after 749 days. Comparing
the two transgenic mouse lines expressing the differentFig. 3. Immunoblots of recombinant sheep prion protein allelic variants PrPARQ (A) a
(C, D: lanes 4, 5). The difference of about 1 kDa in the molecular mass of the PrPSc s
mubo-PrPC and mushp-PrPC (E, F) after incubation with Me7-PrPSc (G, H: lanes 2, 3
PrPC (F: lanes 2–5) whereas there is no comparable fragment detected in the case ochimeric PrP constructs, Tgmushp XIX mice show distinctly
shorter incubation times than Tgmubo XIII mice after
challenge with all five inocula. The most interesting
difference, however, was seen after challenge with the scrapie
strains ME7 and Chandler, that induced very short incubation
times of 182 and 152 days in Tgmushp XIX mice and that
hardly induced disease at all in Tgmubo XIII mice although
these two mouse lines only differ in four amino acids of the
expressed prion protein (Table 1).nd PrPARR (B) after incubation with Me7-PrPSc (C, D: lanes 2, 3) and BSE-PrPSc
eed is transmitted to the particular PrPres. Immunoblots of recombinant chimeric
) and BSE-PrPSc (G, H: lanes 4, 5). PrPres can be detected in the case of mushp-
f mubo-PrPC (E).
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PrPres
The intrinsic convertibility of chimeric mubo-PrPC and
mushp-PrPC was probed in a cell-free conversion assay under
semi-native (i.e. non-denaturing) conditions, where purified
mouse Me7-PrPSc was used as a seed and structurally renaturedFig. 4. Immunoblots of recombinant chimeric mushp-PrPCS96G (A), mushp-PrPCN14
Me7-PrPSc (lanes 2, 3) or BSE-PrPSc (lanes 4, 5). PK resistant PrP is visualized by usin
PrPSc used as seed, which was visualized by a specific polyclonal antibody Ra10. Ev
Me7-PrPSc (C, D), BSE-PrPSc induces a conversion of mushp-PrPCN142S and mushp
PrPSc was not able to induce a conversion in mushp-PrPCN142S or mushp-PrPCQ185
converted by both seeds, Me7-PrPSc as well as BSE-PrPSc (A, E: lanes 2–5). The sli
transferred to the PrPres of the mutant chimeric mushp-PrPC.and affinity purified procaryotic PrPC was used as a template.
PrPC from sheep carrying the PrPARQ (easily convertible into the
pathogenic isoform) or the PrPARR (not convertible under the
applied conditions) allele in homozygosity were used as positive
and negative controls for the conversion assay (Figs. 2, 3A –D).
After an incubation of mushp-PrPC as a template and mouse
Me7-PrPSc as a seed for 3 days at 37 °C, a PrPres fragment of2S (B), mushp-PrPCY154H (E) and mushp-PrPCQ185E (F) after incubation with
g mab L42. Immunoblot lanes on panels C, D, G and H depict the corresponding
en though the BSE-PrPSc signal on the immunoblot is not as strong as the one of
-PrPCQ185E into a partially PK resistant fragment (B, F: lanes 4, 5), whiles Me7-
E into PrPres (B, F: lanes 2, 3). Mushp-PrPCS96G and mushp-PrPCY154H were
ght difference in the molecular mass between Me7-PrPSc and BSE-PrPSc is also
Table 2
Overview of the chimeric PrPCs which were examined for their convertibility
using either Me7-PrPSc or BSE-PrPSc as seeds
Identification of PrPC Convertibility (Me7-PrPSc) Convertibility (BSE-PrPSc)
Mubo − −
Mushp + +
Mushp S96G + +
Mushp N142S − +
Mushp Y154H + +
Mushp Q185E − +
Mushp 96–142 − +
Mushp 96–142–154 − +
Mubo-PrPC was the only construct which was not converted by any of the PrPSc
seeds.
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L42. In contrast, no PrPres was detectable after the same
treatment when mubo-PrPC was used as a template (Figs. 3E–
H). These cell-free conversion results were in accordance with
the in vivo findings described above.
3.3. Conversion of mushp-PrPC mutants
Mushp- and mubo-PrPC differ in only four amino acids, at
positions 96, 142, 154 and 185 (Fig. 1). In order to find out
which of these four polymorphisms were responsible for the
resistance of mubo-PrPC, we mutated each of these amino
acids in mushp-PrPC, either alone or in different combina-
tions. Residue 96 is positioned in the flexible N-terminal
region of PrPC, which is not well structured. Serine was
substituted by glycine in mushp-PrPCS96G. Residue 142 is
located in the vicinity of the first α-helix in the loop close to
the third helix. Asparagine was replaced by serine in mushp-
PrPCN142S. Mushp-PrPCY154H was created by the substitu-
tion of tyrosine by histidine. This residue is localised at the
end of the first α-helix and the amino acid side chain points to
the outside of the PrPC molecule. Glutamine was replaced by
glutamic acid in mushp-PrPCQ185E at residue 185 which is
located in the second half of α-helix two. In the three-
dimensional structure of PrP, glutamine as well as glutamic
acid point towards the first structured parts of PrPC.
The convertibility of mutant mushp-PrPC into its PrPres
counterpart was not affected when serine was changed to
glycine at residue 96 (mushp-PrPCS96G) (Fig. 4A) or when
tyrosine was changed to histidine at residue 154 (mushp-PrPC
Y154H) (Fig. 4E). However, when residue 142 was changed
from asparagine to serine (mushp-PrPCN142S) (Fig. 4B) or
when residue 185 was changed from glutamine to glutamic acid
(mushp-PrPCQ185E) (Fig. 4F), the formation of a PrPres
fragment could not be detected.
In the next step, we inserted combinations of several
mutations in one protein. After the substitution from serine to
glycine at residue 96 and asparagine to serine at residue 142
(mushp-PrPC 96–142) there was no conversion detectable (Fig.
6B). Moreover, when tyrosine was additionally changed to
histidine at residue 154 (mushp-PrPC 96–142–154), PrPC was
also inconvertible (Fig. 6B).Fig. 5. Immunoblot of Me7-PrPSc and BSE-PrPSc after treatment with
proteinase K. Due to a difference in the PK cleavage site, which is located
further C-terminally in BSE-PrPSc than it is in Me7-PrPSc a slight shift in the
molecular mass of about 1 kDa can be detected (small arrows) between Me7-
PrPSc and BSE-PrPSc.These results indicate that point mutations at amino acid
residues 142 and 185, separately or in combinations, have a
negative influence on the convertibility of chimeric mushp-PrPC
to PrPres when Me7-PrPSc is used as a seed (Fig. 4B, D; F, H).
3.4. Mouse derived BSE-PrPSc induced conversion of chimeric
PrPC to PrPres
Results obtained with mouse passaged BSE-PrPSc seeds and
mushp-PrPC or mubo-PrPC were identical to those obtained
with ME7-PrPSc, i.e. mushp-PrPC was convertible, while mubo-
PrPC was not (Fig. 3E, F).
3.5. Mouse derived BSE-PrPSc conversion of chimeric PrPC
mutants
Unlike mouse scrapie Me7-PrPSc mouse passaged BSE
induced a conversion of all mutant chimeric PrPC constructs
(Fig. 4). The strain specific difference of approximately 1 kDa
in molecular mass after PK digestion (Fig. 5) was maintained
after the in vitro conversion. The newly formed PrPres was
approximately 1 kDa lower in molecular mass when BSE-
PrPSc was used as a seed than the PK digested PrPres that was
newly formed after incubation with Me7-PrPSc as a seed
(Figs. 3, 4).
The results of the convertibility assays of all PrP constructs
with Me7-PrPSc and BSE-PrPSc are summarized in Table 2.
3.6. Quantitative amounts of PrPres
The relative ratio of converted prion protein was up to
seven percent of the amount of PrPC that was initially set into
the reaction (Fig. 6A). Mushp-PrPC showed almost equal
conversion rates after incubation with Me7-PrPSc or BSE-
PrPSc. Mushp-PrPCS96G as well as mushp-PrPCS154H were
more efficiently converted by BSE-PrPSc than by Me7-PrPSc
as the ratio of BSE-PrPSc induced PrPres was about 1.5 times
higher than that of Me7-PrPSc induced PrPres. This was even
more obvious for the mutants mushp-PrPCN142S, mushp
PrPCQ185E, mushp-PrPC96–142 and mushp-PrPC96-142–
154, since Me7-PrPSc did not provoke any conversion of
theses mutants, while the conversion rate was approximately
Fig. 6. Quantitative amounts of newly formed PrPres in percent as compared to
the total amount of PrPC which was used in the conversion assay. Concerning the
mutant chimeric mushp-PrPCS96G/mushp-PrPCY154H the effectivity of con-
version is higher if BSE-PrPSc is used as seed than if Me7-PrPSc is used. In
contrast, the positive control PrPARQ shows higher amounts of newly formed
PrPres if the incubation is carried out with Me7-PrPSc instead of BSE-PrPSc (A).
Even thoughMe7-PrPSc is not able to induce a conversion of the mutant chimeric
mushp-PrPCs, the quantitative amount of newly formed PrPres which can be
detected after an incubationwith BSE-PrPSc ranged at least up to 2% compared to
the volume of undigested PrPC (B).
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BSE-PrPSc as a seed (Fig. 6B).
4. Discussion
We have generated transgenic mice overexpressing either
wild-type bovine (Tgbov XV) or ovine (Tgshp XI) PrPC or
murine/bovine (Tgmubo XIII) or murine/ovine (Tgmushp
XIX) PrPC chimera. These animals were challenged with
either murine or ovine scrapie or bovine BSE prions. Al-
though mubo-PrPC and mushp-PrPC differ in only four amino
acids (Fig. 1), Tgmushp XIX mice were highly susceptible,
whereas Tgmubo XIII mice were almost resistant to an
infection with mouse scrapie ME7 and Chandler. They also
displayed a low susceptibility (incubation times of at least
560 days) to bovine BSE, sheep scrapie, and the scrapie strain
22A (Table 1). We therefore postulate the occurrence of strain-
specific interactions of PrPSc with certain amino acid positions
of PrP, since the scrapie strains ME7 and Chandler induced
very short incubation times of 182 and 152 days in Tgmushp
XIX mice while Tgmubo XIII mice hardly developed the
disease at all.The resistance of Tgmubo XIII mice is highly unlikely to be
caused by a mismatch at the postulated protein X binding sites at
residues 183 and 185 of PrPC since the highly susceptible Tgbov
XV mice encode a protein in which these amino acids are
identical to that of TgmuboXIII mice. Since all mouse lines used
in this study showed an expression rate of 8–16 fold, this
difference must be caused by the differing four amino acids at
positions 96, 142, 154, and 185 between Tgbov XVand Tgmubo
XIII PrPC.
Similar effects were also seen, when a cell-free PrP
conversion system was employed. Although this system does
not fully reflect the in vitro situation, since a procaryotic PrPC is
used which is not posttranslationally modified in the same way
as eucaryotically expressed PrP, the applied system is
considered appropriate to study the general effects of point
mutations on the convertibility of the protein. However, a
distinct quantification of the conversion efficiency is difficult
within this system. Further studies using more authentical
systems such as PMCA are anticipated for the future.
Me7-PrPSc as well as BSE-PrPSc were able to induce a
conversion of mushp-PrPC to PrPres in the cell-free assay. In
contrast, it was not possible to detect any PrPres when the
conversion experiment was carried out with mubo-PrPC as a
template. Thus the difference of the four amino acids at
positions 96, 142, 154 and 185 appears to be also responsible
for the inconvertibility of mubo-PrPC in vitro. The influence
of the amino acid sequence on the convertibility and therefore
on the development of disease has already be shown in
numerous studies [26,27]. Scrapie susceptibility of sheep is
known to be linked to certain PrP genotypes [28]. Especially
polymorphisms at codons 136, 154 and 171 are known to be
associated with susceptibility and disease phenotype [7].
These findings have been successfully reproduced in in vitro
systems, either in cell culture or in cell-free conversion assays
[21,29]. Since prion proteins of different species only show
minor structural modifications [30], it can be assumed that
mubo-PrPC and mushp-PrPC also do not display major
differences in their three dimensional structure. Even though
single or few amino acid substitutions do not necessarily
change the structural properties or the overall stability of PrPC
[31], they may have an impact on the protein interactions prior
to and/or during the conversion process as well as on the
binding affinity to yet unknown cofactors. Moreover, the
amino acid sequence determines the intrinsic stability of PrPC
and therefore its propensity to conversion and the formation of
amyloid fibrils. Such effects have been proposed regarding the
allele specific polymorphisms particularly within ovine PrPC
in sheep [32].
As the in vitro results were very well in accordance with the
in vivo findings we tried to elucidate the molecular mechanisms
of the conversion reaction by introducing relevant mutations
(singular or in combination) at positions 96, 142, 154, or 185 of
mushp-PrPC. These mutants were co-incubated in a cell-free
conversion assay using Me7-PrPSc as a seed. These studies
revealed that the mutations at residues 96 and 154 had no effect
(Fig. 4A, E), while altering positions 142 and 185 rendered
mushp-PrPC inconvertible by Me7-PrPSc seeds (Fig. 4B, F).
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replaced by glycin (non-polar with a very short side chain). This
residue is located in the flexible, structurally not well-defined
part of PrPC. This is probably the reason why this substitution
did not have a negative effect on the convertibility of PrPC in
our experiments. However, it has already been reported that the
N-terminus of PrPC does play a role in the prion conversion, as
the deletion of amino acids up to residue 124 of hamster PrP
resulted in a reduced in vivo susceptibility and a lower in vitro
efficiency of PrPres formation [33].
The Y154H substitution which also had no effect on the cell-
free conversion efficiency of mushp-PrPC in our study using
Me7-PrPSc is located just after the first α-helix. However, it can
be assumed that the dipolar character of the α-helix is stronger
supported by the presence of tyrosine than it is by histidine,
because tyrosine has a polar side chain (phenolic hydroxy-
group), whereas histidine carries an uncharged or positive polar
side chain.
In contrast, the two mutations N142S and Q185E rendered
mushp-PrPC inconvertible using Me7-PrPSc (Fig. 4B, F).
Asparagine and glutamine at residues 142 (mushp-PrPCN142S)
and 185 (mushp-PrPC Q185E) are two amino acids which are
both known to stabilise secondary structure elements via H-
bonds. Residue 142 is located close to the first α-helix residue,
whereas 185 lies within the second α-helix. In mushp-PrPC-
N142S asparagine is substituted by serine. Both amino acids
exhibit an uncharged polar side chain but serine is noticeably
smaller than asparagine. Furthermore, serine misses the terminal
carboxyamide group which enables asparagine to form H-
bonds, which again enhance the intrinsic stability of the
molecule. Thus, the exchange might result in a lower stability of
mushp-PrPCN142S and therefore lead to negative results in cell
free conversion experiments, as unstable proteins are more
easily degraded by endogenous proteases [32]. On the other
hand in mushp-PrPCQ185E glutamine carrying an uncharged
polar side chain was substituted by glutamic acid with a charged
polar side chain. Like in mushp-PrPCN142S the replacement of
a stabilising amino acid at residue 185 hampered the conversion
of this mutated protein into its PrPres counterpart. This is due to
the terminally located carboxyamide group present in gluta-
mine, since H-bonds can be built both from the oxygen and
from the amino group.
In addition to these single point mutations we gradually
mutated mushp-PrPC to mubo-PrPC by consecutively introdu-
cing the amino acids substitutions S96G, N142S, Y154H and
Q185E. However, as soon as the S96G substitution was
combined with the N142S mutation, mushp-PrPC lost its
convertibility and did not regain it by the additional replacement
of Y154H.
It has been reported that the A136Vand Q171R mutations in
the PrPARQ, PrPARR and PrPVRQ alleles which modulate the
scrapie resistance of sheep, seem to alter the structural stability
of ovine PrPC by preventing the formation of stabilising H-
bonds at the surface of the protein [34]. In accordance with this
model we could show that PrPARQ but not PrPARR is convertible
in the in the cell free conversion assay, independent of whether
BSE or Me7 prions are used [21].All mushp-PrPC mutants were eventually incubated with
mouse passaged BSE-PrPSc. Surprisingly, the detection of a
PrPres fragment was possible in every mutant but not in mubo-
PrPC (Figs. 3, 4). Although Me7-PrPSc and BSE-PrPSc harbour
the same amino acid sequence (both derived from passages in
C57Bl/6 mice), they differ in strain specific characteristics: the
incubation time for mouse BSE in C57Bl/6 mice is about
177 days whereas the incubation time for mouse scrapie Me7 is
139 days in the same mouse line [25]. Moreover, BSE and
scrapie display distinct differences in their glycosylation pattern
[11,36] as well as the molecular mass after PK digestion (Fig.
5): The PK cleavage site of BSE-PrPSc is located further N-
terminally than in Me7-PrPSc. Therefore, the residual Me7-
PrPSc after PK treatment has a slightly higher molecular mass
than the PK resistant part of BSE-PrPSc [35].
Both distinctive features might refer to an agent specific
three dimensional structure of PrPSc, which obviously enables
the pathogen to transmit its specific characteristics to the newly
formed PrPres during the conversion process: PrPres showed a
by one kDa reduced molecular mass after PK-digestion when
the conversion reaction was carried out with BSE-PrPSc as a
seed as compared to the banding pattern that was obtained after
incubation with Me7-PrPSc as a seed. The mechanism by which
such strain specific features are imparted on PrPres still remains
unclear. Most probably this question will not be able to be
answered as long as no high-resolution structural analysis of
PrPSc is available.
The observation that BSE-PrPSc but not Me7-PrPSc was
capable to convert mushp-PrPCN142S and mushp-PrPCQ185E
shows that the conversion efficiency of a PrP mutant can also
strongly depend on strain specific effects. Although the precise
underlying mechanism for this specific preference still remains
to be elucidated, it already points at the importance of single
amino acid positions for the interaction between the PrPC
template and the PrPSc seed prior to and/or during the
conversion process.References
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